|
1
|
DeSantis CE, Siegel RL, Sauer AG, Miller
KD, Fedewa SA, Alcaraz KI and Jemal A: Cancer statistics for
African Americans, 2016: Progress and opportunities in reducing
racial disparities. CA Cancer J Clin. 66:290–308. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tørring ML, Falborg AZ, Jensen H, Neal RD,
Weller D, Reguilon I; ICBP Working Group, ; Menon U and Vedsted P:
Advanced-stage cancer and time to diagnosis: An international
cancer benchmarking partnership (ICBP) cross-sectional study. Eur J
Cancer Care (Engl). May 22–2019.(Epub ahead of print). View Article : Google Scholar
|
|
3
|
Dawson S, Apcher S, Mee M, Higashitsuji H,
Baker R, Uhle S, Dubiel W, Fujita J and Mayer RJ: Gankyrin is an
ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the
S6 ATPase of the 26 S proteasome. J Biol Chem. 277:10893–10902.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Higashitsuji H, Itoh K, Nagao T, Dawson S,
Nonoguchi K, Kido T, Mayer RJ, Arii S and Fujita J: Reduced
stability of retinoblastoma protein by gankyrin, an
oncogenicankyrin-repeat protein overexpressed in hepatomas. Nat
Med. 6:96–99. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Krzywda S, Brzozowski AM, Higashitsuji H,
Fujita J, Welchman R, Dawson S, Mayer RJ and Wilkinson AJ: The
crystal structure of gankyrin, an oncoprotein found in complexes
with cyclin-dependent kinase 4, a 19 S proteasomal ATPase
regulator, and the tumor suppressors Rb and p53. J Biol Chem.
279:1541–1545. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Higashitsuji H, Higashitsuji H, Itoh K,
Sakurai T, Nagao T, Sumitomo Y, Masuda T, Dawson S, Shimada Y,
Mayer RJ and Fujita J: The oncoprotein gankyrin binds to MDM2/HDM2,
enhancing ubiquitylation and degradation of p53. Cancer Cell.
8:75–87. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Y, Li HH, Fu J, Wang XF, Ren YB, Dong
LW, Tang SH, Liu SQ, Wu MC and Wang HY: Oncoprotein p28 GANK binds
to RelA and retains NF-kappaB in the cytoplasm through nuclear
export. Cell Res. 17:1020–1029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng T, Hong X, Wang J, Pei T, Liang Y,
Yin D, Song R, Song X, Lu Z, Qi S, et al: Gankyrin promotes tumor
growth and metastasis through activation of IL-6/STAT3 signaling in
human cholangiocarcinoma. Hepatology. 59:935–946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu J, Chen Y, Cao J, Luo T, Qian YW, Yang
W, Ren YB, Su B, Cao GW, Yang Y, et al: p28GANK overexpression
accelerates hepatocellular carcinoma invasiveness and metastasis
via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α
pathways. Hepatology. 53:181–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Man JH, Liang B, Gu YX, Zhou T, Li AL, Li
T, Jin BF, Bai B, Zhang HY, Zhang WN, et al: Gankyrin plays an
essential role in Ras-induced tumorigenesis through regulation of
the RhoA/ROCK pathway in mammalian cells. J Clin Invest.
120:2829–2841. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong LW, Yang GZ, Pan YF, Chen Y, Tan YX,
Dai RY, Ren YB, Fu J and Wang HY: The oncoprotein p28GANK
establishes a positive feedback loop in β-catenin signaling. Cell
Res. 21:1248–1261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang J, Yang Y, Zhang Z, He Y, Liu Z, Yu
Y, Wu S, Cai B and Feng Y: Gankyrin plays an essential role in
estrogen-driven and GPR30-mediated endometrial carcinoma cell
proliferation via the PTEN/PI3K/AKT signaling pathway. Cancer Lett.
339:279–287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mizuno H, Kitada K, Nakai K and Sarai A:
PrognoScan: A new database for meta-analysis of the prognostic
value of genes. BMC Med Genomics. 2:182009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo Q, He Y, Sun L, Kong C, Cheng Y and
Zhang G: In silico detection of potential prognostic circRNAs
through a re-annotation strategy in ovarian cancer. Oncol Lett.
17:3677–3686. 2019.PubMed/NCBI
|
|
16
|
Keen JC and Moore HM: The genotype-tissue
expression (GTEx) project: Linking clinical data with molecular
analysis to advance personalized medicine. J Pers Med. 5:22–29.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Silverberg SG: Histopathologic grading of
ovarian carcinoma: A review and proposal. Int J Gynecol Pathol.
19:7–15. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pecorelli S, Benedet JL, Creasman WT and
Shepherd JH: FIGO staging of gynecologic cancer. 1994–1997 FIGO
committee on gynecologic oncology. international federation of
gynecology and obstetrics. Int J Gynaecol Obstet. 65:243–249. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen J, Bai M, Ning C, Xie B, Zhang J,
Liao H, Xiong J, Tao X, Yan D, Xi X, et al: Gankyrin facilitates
follicle-stimulating hormone-driven ovarian cancer cell
proliferation through the PI3K/AKT/HIF-1 α/cyclin D1 pathway.
Oncogene. 35:2506–2517. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meng Y, He L, Guo X, Tang S, Zhao X, Du R,
Jin J, Bi Q, Li H, Nie Y, et al: Gankyrin promotes the
proliferation of human pancreatic cancer. Cancer Lett. 297:9–17.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bai Z, Tai Y, Li W, Zhen C, Gu W, Jian Z,
Wang Q, Lin JE, Zhao Q, Gong W, et al: Gankyrin activates IL-8 to
promote hepatic metastasis of colorectal cancer. Cancer Res.
73:4548–4558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ortiz CM, Ito T, Tanaka E, Tsunoda S,
Nagayama S, Sakai Y, Higashitsuji H, Fujita J and Shimada Y:
Gankyrin oncoprotein overexpression as a critical factor for tumor
growth in human esophageal squamous cell carcinoma and its clinical
significance. Int J Cancer. 122:325–332. 2010. View Article : Google Scholar
|
|
23
|
Zhen C, Chen L, Zhao Q, Liang B, Gu YX,
Bai ZF, Wang K, Xu X, Han QY, Fang DF, et al: Gankyrin promotes
breast cancer cell metastasis by regulating Rac1 activity.
Oncogene. 32:3452–3460. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qin X, Wang X, Liu F, Morris LE, Wang X,
Jiang B and Zhang Y: Gankyrin activates mTORC1 signaling by
accelerating TSC2 degradation in colorectal cancer. Cancer Lett.
376:83–94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lloyd K: The resurgence of platinum-based
cancer chemotherapy. Nat Rev Cancer. 7:573–584. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun W, Ding J, Wu K, Ning BF, Wen W, Sun
HY, Han T, Huang L, Dong LW, Yang W, et al: Gankyrin-mediated
dedifferentiation facilitates the tumorigenicity of rat hepatocytes
and hepatoma cells. Hepatology. 54:1259–1272. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qian YW, Chen Y, Yang W, Fu J, Cao J, Ren
YB, Zhu JJ, Su B, Luo T, Zhao XF, et al: p28 GANK prevents
degradation of oct4 and promotes expansion of tumor-initiating
cells in hepatocarcinogenesis. Gastroenterology. 142:1547–1558.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mine H, Sakurai T, Kashida H, Matsui S,
Nishida N, Nagai T, Hagiwara S, Watanabe T and Kudo M: Association
of Gankyrin and Stemness factor expression in human; Colorectal
cancer. Dig Dis Sci. 58:2337–2344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dai RY, Chen Y, Fu J, Dong LW, Ren YB,
Yang GZ, Qian YW, Cao J, Tang SH, Yang SL and Wang HY: p28GANK
inhibits endoplasmic reticulum stress-induced cell death via
enhancement of the endoplasmic reticulum adaptive capacity. Cell
Res. 19:1243–1257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Luo T, Fu J, Xu A, Su B, Ren Y, Li N, Zhu
J, Zhao X, Dai R, Cao J, et al: PSMD10/gankyrin induces autophagy
to promote tumor progression through cytoplasmic interaction with
ATG7 and nuclear transactivation of ATG7 expression. Autophagy.
12:1355–1371. 2016. View Article : Google Scholar : PubMed/NCBI
|
